<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="2329">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 14, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04779047</url>
  </required_header>
  <id_info>
    <org_study_id>REC-H-PhBSU-21011</org_study_id>
    <nct_id>NCT04779047</nct_id>
  </id_info>
  <brief_title>Comparative Therapeutic Efficacy and Safety of Different Antiviral and Anti Inflammatory Drugs in COVID-19 Patients.</brief_title>
  <official_title>Comparative Therapeutic Efficacy and Safety of Remdesivir Plus Lopinavir/ Ritonavir and Tocilizumab Versus Hydroxychloroquine Plus Ivermectin and Tocilizumab in COVID-19 Patients.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>October 6 University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Beni-Suef University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>October 6 University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Comparison outcomes of a large cohort of moderate and severe COVID-19 patients received&#xD;
      different Antiviral and Anti Inflammatory Drugs.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Aim of the study&#xD;
&#xD;
        1. To assess the difference in patients' clinical status improvement between patients.&#xD;
&#xD;
        2. To detect time to improvement in oxygenation among both groups.&#xD;
&#xD;
        3. To detect duration of hospitalization and mortality rate in both groups.&#xD;
&#xD;
        4. To detect incidence and duration of mechanical ventilation in both treatment arms.&#xD;
&#xD;
        5. To monitor of adverse events of both drugs&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">October 1, 2020</start_date>
  <completion_date type="Anticipated">April 5, 2021</completion_date>
  <primary_completion_date type="Anticipated">March 10, 2021</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage of clinical cure in each arm</measure>
    <time_frame>through an average of 5-7 days</time_frame>
    <description>Proportion of cured patients in the interventional group versus the proportion of cured patients in the control group before and after starting drugs</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">150</enrollment>
  <condition>Covid19</condition>
  <condition>Pneumonia</condition>
  <arm_group>
    <arm_group_label>group 1</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Remdesivir will be administrated intravenously (IV) at a dose of 200 mg at day 1 then 100 mg once daily for 5 days and Lopinavir / ritonavir at a dose of 400 /100 once daily for 5 days plus tocilizumab 800 mg once</description>
  </arm_group>
  <arm_group>
    <arm_group_label>group 2</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Hydroxychloroquine will be administrated at a dose of 400 mg twice daily at day 1 then 200 mg twice daily for 5 days and Ivermectin 36 mg at day 1,3 and 6 plus tocilizumab 800 mg once.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Remdesivir</intervention_name>
    <description>Remdesivir will be administrated intravenously (IV) at a dose of 200 mg at day 1 then 100 mg once daily for 5 days.</description>
    <arm_group_label>group 1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Hydroxychloroquine</intervention_name>
    <description>Hydroxychloroquine will be administrated at a dose of 400 mg twice daily at day 1 then 200 mg twice daily for 5 days.</description>
    <arm_group_label>group 2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tocilizumab</intervention_name>
    <description>Tocilizumab 800 mg once.</description>
    <arm_group_label>group 1</arm_group_label>
    <arm_group_label>group 2</arm_group_label>
    <other_name>Actemra</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Lopinavir/ Ritonavir</intervention_name>
    <description>Lopinavir / ritonavir at a dose of 400 /100 once daily for 5 days.</description>
    <arm_group_label>group 1</arm_group_label>
    <other_name>kaletra</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ivermectin</intervention_name>
    <description>Ivermectin 36 mg at day 1,3 and 6.</description>
    <arm_group_label>group 2</arm_group_label>
    <other_name>Iverazine</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Hospitalized adult patients with pneumonia evidenced by chest CT scan.&#xD;
&#xD;
          -  Laboratory (RT-PCR) confirmed infection with 2019-nCoV or strongly suspected to be&#xD;
             infected with SARS-COV2 with confirmation studies pending.&#xD;
&#xD;
          -  And at least one of the following:&#xD;
&#xD;
               1. Respiratory frequency ≥30/min.&#xD;
&#xD;
               2. Blood oxygen saturation ≤93% on room air (RA).&#xD;
&#xD;
               3. Partial pressure of arterial oxygen to fraction of inspired oxygen ratio&#xD;
                  (PaO2/FiO2) &lt;300.&#xD;
&#xD;
               4. Worsening of lung involvement, defined as an increase in number and/or extension&#xD;
                  of pulmonary areas of consolidation, need for increased FiO2 to maintain stable&#xD;
                  O2 saturation, or worsening O2 saturation of &gt;3% with stable FiO2.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Baseline elevation of alanine aminotransferase (ALT) or aspartate aminotransferase&#xD;
             (AST) levels &gt; 3-fold the upper limit of the normal range.&#xD;
&#xD;
          -  Pregnancy.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>88 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Marian Boshra, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Beni-Suef University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Ahmed E Abou warda, BSc</last_name>
    <phone>00201007647696</phone>
    <email>ahmed.essam@o6u.edu.eg</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Rania M Sarhan, PhD</last_name>
    <phone>0001008789509</phone>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Beni-suef University</name>
      <address>
        <city>Banī Suwayf</city>
        <country>Egypt</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Rania M Sarhan, PhD</last_name>
    </contact>
  </location>
  <location_countries>
    <country>Egypt</country>
  </location_countries>
  <verification_date>March 2021</verification_date>
  <study_first_submitted>February 25, 2021</study_first_submitted>
  <study_first_submitted_qc>March 1, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">March 3, 2021</study_first_posted>
  <last_update_submitted>March 15, 2021</last_update_submitted>
  <last_update_submitted_qc>March 15, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">March 17, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>October 6 University</investigator_affiliation>
    <investigator_full_name>Ahmed Essam</investigator_full_name>
    <investigator_title>Principle Investigator</investigator_title>
  </responsible_party>
  <keyword>covid19</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pneumonia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ritonavir</mesh_term>
    <mesh_term>Lopinavir</mesh_term>
    <mesh_term>Hydroxychloroquine</mesh_term>
    <mesh_term>Ivermectin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

